Patients with epidermal growth factor receptor (EGFR) positive non-small cell lung cancer (NSCLC) show improved response rates when treated with tyrosine kinase inhibitors (TKIs) such as erlotinib. However, standard daily dosing of erlotinib often does not reach therapeutic concentrations within the cerebrospinal fluid (CSF), resulting in progression of central nervous system (CNS) disease. Intermittent, high dose administration of erlotinib reaches therapeutic concentrations within the CSF and is well-tolerated in patients.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lq3g6Q
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2Gchesc via IFTTT
-
Abstract Determining the cause of unexplained death in all age groups, including infants, is a priority in forensic medicine. The triple r...
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2BeOBVJ via IFTTT
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2rxuJIO via IFTTT
-
Abstract In this paper we present the study of a skull belonging to a young male from the Italian Bronze Age showing three perimortem inju...
-
Abstract To measure integral doses in image-guided radiation therapy, we developed an integral condenser dosimeter comprising a disposable...
-
Objectives. To assess the association between short-term postoperative cognitive dysfuction (POCD) and inflammtory response in patients unde...
-
Abstract Layer-by-layer (LbL) dip coating, accompanying with the use of micelle structure, allows hydrophobic molecules to be coated on me...
-
This paper presents an adaptive multiuser transceiver scheme for DS-CDMA systems in which pilot symbols are added to users’ data to estimate...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου